Blueshift Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-1,348
Closed -$240K 383
2024
Q4
$240K Sell
1,348
-5,441
-80% -$1M 0.09% 307
2024
Q3
$1.34M Buy
6,789
+738
+12% +$138K 0.33% 63
2024
Q2
$1.04M Buy
+6,051
New +$1M 0.35% 70
2024
Q1
Sell
-5,004
Closed -$775K 266
2023
Q4
$775K Buy
+5,004
New +$730K 0.41% 67
2023
Q3
Sell
-6,437
Closed -$867K 267
2023
Q2
$867K Buy
6,437
+1,577
+32% +$231K 0.33% 67
2023
Q1
$775K Buy
4,860
+1,751
+56% +$268K 0.32% 86
2022
Q4
$502K Buy
3,109
+43
+1% +$6.59K 0.23% 117
2022
Q3
$411K Buy
+3,066
New +$440K 0.09% 325
2022
Q2
Sell
-14,808
Closed -$2.4M 643
2022
Q1
$2.4M Buy
+14,808
New +$2.15M 0.22% 125
2021
Q4
Sell
-9,863
Closed -$1.06M 801
2021
Q3
$1.06M Sell
9,863
-164,112
-94% -$18.8M 0.06% 390
2021
Q2
$19.6M Buy
173,975
+144,589
+492% +$16.3M 1.07% 9
2021
Q1
$3.18M Buy
29,386
+2,743
+10% +$293K 0.33% 68
2020
Q4
$2.85M Buy
26,643
+16,253
+156% +$1.56M 0.34% 75
2020
Q3
$910K Buy
+10,390
New +$978K 0.12% 225

Other funds holding ABBV

Blueshift Asset Management's ABBV Position: Q1 2025 in Review

Blueshift Asset Management sold out of AbbVie (ABBV) in Q1 2025, closing a stake of 1,348 shares — an estimated $240K sold.

Blueshift Asset Management first reported a position in ABBV in Q3 2020 and held it in 14 quarters. The position peaked at $19.6M in Q2 2021. 3,819 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

  • Blueshift Asset Management reported no remaining AbbVie position as of Q1 2025 after selling out during the quarter.
  • Blueshift Asset Management sold 1,348 AbbVie shares in Q1 2025, an estimated $240K.
  • Blueshift Asset Management first reported a position in AbbVie in Q3 2020 and held it in 14 quarters.
  • Blueshift Asset Management's AbbVie position peaked at $19.6M in Q2 2021.
  • 3,819 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on Blueshift Asset Management's 13F filing for Q1 2025, filed 8 May 2025.